tirzepatide news september 27 2025 New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Drug maker cutting prices for

Starting Your Semaglutide Treatment The initial dose of Semaglutide is typically 0.25 mg, administered once a week for four weeks

This highlights known brain effects of GLP-1/GIP agonists: they quiet ventral tegmental area dopamine neurons, which helps silence food noise or alcohol cravings but can also dampen curiosity, music, sex, and project satisfaction

LifeMD's consultation model does not include genetic testing

Nausea often improves as the body adjusts to tirzepatide, usually after a few weeks

People dont know, especially Bri (00:21:10):That true

H ASCO GU 2026 ASCO GU 2026 (American Society of Clinical Oncology Genitourinary Cancers Symposium) is one of the leading international events dedicated to genitourinary cancers, bringing together specialists from around the world to discuss the latest advances in diagnosis, treatment, and clinical research